Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Colon Cancer

11 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCGI15122

    01/15/2016

    Research Use of Human Biospecimens from Colorectal Cancer Patients (Pilot Study)

    Other

    VICCGI99003

    08/01/2010

    Personalized Prevention of Colorectal Cancer

    Other

    VICCGI0721

    01/09/2007

    Vanderbilt Hereditary Colorectal Cancer Registry

    Prevention

    GIS0820-M

    07/09/2013

    A double blind placebo controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colon ca in patients with stage 0-III colon ca; phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac

    Treatment

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Treatment

    VICCGI1623

    03/16/2016

    A Randomized, Controlled, Parallel, Multicenter Study Assessing Perfusion Outcomes with PINPOINT? Near Infrared Fluorescence Imaging in Low Anterior Resection

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    VICCGIP1536

    10/26/2015

    A Phase 1 Study of Alisertib (MLN8237) in combination with mFOLFOX in Gastrointestinal Tumors

    Treatment

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification


    Print this page for your doctor